Microvascular and macrovascular benefits of GLP-1 receptor agonists
This presentation is designed for pharmacists and pharmacy technicians at ChristianaCare Hospital. It will address current diabetes treatment guidelines and the data evaluating the effects GLP-1 RAs have on microvascular and macrovascular complications and describe the proposed mechanism by which GLP-1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). Pharmacists will review the mechanism of action of GLP-1 receptor agonist, discern between management of glucose metabolism and the reduction in CVD. By the end of this presentation pharmacist will be able to identify which GLP-1 RA have been indicated to reduce CVD and reduce mortality.
Target Audience
- Pharmacists
- Pharmacy technicians
Learning Objectives
Pharmacist learning objectives
- Describe the mechanism of action, efficacy and common adverse drug reactions associated with GLP-1 RA agents
- Discuss the data surrounding microvascular and macrovascular effects of GLP-1 RA agents
- Use available data and the 2020 American Diabetes Association (ADA) guidelines and 2020 American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) guidelines to determine GLP-1 RA place in therapy
Pharmacy technician learning objectives
- List the FDA approved GLP-1RA agents
Additional Information
Attachment | Size |
---|---|
![]() | 23.3 KB |
![]() | 124.3 KB |

Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CEU – Attendance